Aposense Ltd Petach (APNSF) 0.2700 $APNSF
Pancreatic Cancer Pipeline Review, H2 2015
M2 - Tue Feb 09, 10:18AM CST
Research and Markets (http://www.researchandmarkets.com/research/r58xq3/pancreatic_cancer) has announced the addition of the "Pancreatic Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pancreatic Cancerand special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Pancreatic CancerOverview - Therapeutics Development - Pipeline Products for Pancreatic Cancer - Overview - Pipeline Products for Pancreatic Cancer - Comparative Analysis - Pancreatic Cancer - Therapeutics under Development by Companies - Pancreatic Cancer - Therapeutics under Investigation by Universities/Institutes - Pancreatic Cancer - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Pancreatic Cancer - Products under Development by Companies - Pancreatic Cancer - Products under Investigation by Universities/Institutes - Pancreatic Cancer - Companies Involved in Therapeutics Development Companies Mentioned - Partial List - 3-V Biosciences, Inc. - 3B Pharmaceuticals GmbH - 4SC AG - AB Science SA - AbbVie Inc. - AbGenomics International, Inc. - Ability Pharma, SL - Acetylon Pharmaceuticals, Inc. - ACF Pharmaceuticals, LLC - Adamed Sp. z o.o. - Adamis Pharmaceuticals Corporation - Aduro BioTech, Inc. - Advantagene, Inc. - Advaxis, Inc. - Agenus, Inc. - AGV Discovery, SAS - AIMM Therapeutics B.V. - Alchemia Limited - Alethia Biotherapeutics Inc. - Allinky Biopharma - Almac Discovery Limited - Altor BioScience Corporation - Ambrx, Inc. - Amgen Inc. - Anavex Life Sciences Corp. - Andarix Pharmaceuticals, Inc. - ANP Technologies, Inc. - APEIRON Biologics AG - Apexigen, Inc. - Aphios Corporation - APIM Therapeutics AS - Apogenix GmbH - Aposense Ltd. - Arch Biopartners, Inc. - Argon Pharma S.L. For more information visit http://www.researchandmarkets.com/research/r5...tic_cancer
ADXS: 8.97 (-0.69), ADRO: 11.73 (-0.54), AVXL: 4.55 (-0.08), AMBX: (), ACH: 7.64 (-0.02), AMGN: 159.19 (-0.68), ADMP: 8.86 (unch), ABBV: 65.00 (-0.09)
Global Melanoma Pipeline Review 2015
M2 - Tue Feb 09, 10:12AM CST
Research and Markets (http://www.researchandmarkets.com/research/xdhrqg/melanoma) has announced the addition of the "Melanoma - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Melanomaand special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - MelanomaOverview - Therapeutics Development - Pipeline Products for Melanoma - Overview - Pipeline Products for Melanoma - Comparative Analysis - Melanoma - Therapeutics under Development by Companies - Melanoma - Therapeutics under Investigation by Universities/Institutes - Melanoma - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Melanoma - Products under Development by Companies - Melanoma - Products under Investigation by Universities/Institutes - Melanoma - Companies Involved in Therapeutics Development Companies Mentioned - Sample List - AB Science SA - AbbVie Inc. - ACF Pharmaceuticals, LLC - Adamis Pharmaceuticals Corporation - Adaptimmune Limited - Aduro BioTech, Inc. - Advaxis, Inc. - Aeterna Zentaris Inc. - Affichem SA - Agalimmune Ltd - Agenus, Inc. - Agilvax, Inc. - AGV Discovery, SAS - AIMM Therapeutics B.V. - Alethia Biotherapeutics Inc. - Altor BioScience Corporation - Amgen Inc. - Anavex Life Sciences Corp. - Antigen Express, Inc. - APEIRON Biologics AG - Aphios Corporation - APO-T B.V. - Aposense Ltd. - Applied Immune Technologies Ltd - Aptose Biosciences Inc. - Arisaph Pharmaceuticals, Inc. - Array BioPharma Inc. - Arrowhead Research Corporation - Astex Pharmaceuticals, Inc. - AstraZeneca Plc - Aurigene Discovery Technologies Limited - Axelar AB - Azaya Therapeutics, Inc. - Basilea Pharmaceutica AG For more information visit http://www.researchandmarkets.com/research/xdhrqg/melanoma
ADXS: 8.97 (-0.69), ADRO: 11.73 (-0.54), ARWR: 6.12 (-0.06), ADMP: 8.86 (unch), AMGN: 159.19 (-0.68), APTO: 2.70 (+0.04), AVXL: 4.55 (-0.08), AZN: 29.73 (+0.06), ABBV: 65.00 (-0.09), ARRY: 3.79 (-0.06)
Colorectal Cancer Therapeutics Development Pipeline Review, H2 2015
M2 - Tue Feb 09, 6:40AM CST
Research and Markets (http://www.researchandmarkets.com/research/44bmjz/colorectal_cancer) has announced the addition of the "Colorectal Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Colorectal Cancerand special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Colorectal CancerOverview - Therapeutics Development - Pipeline Products for Colorectal Cancer- Overview - Pipeline Products for Colorectal Cancer- Comparative Analysis - Colorectal Cancer- Therapeutics under Development by Companies - Colorectal Cancer- Therapeutics under Investigation by Universities/Institutes - Colorectal Cancer- Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Colorectal Cancer- Products under Development by Companies - Colorectal Cancer- Products under Investigation by Universities/Institutes - Colorectal Cancer- Companies Involved in Therapeutics Development Companies Mentioned - Sample List of the 200 Companies Featured - 2cureX ApS - 3-V Biosciences, Inc. - 4SC AG - AB Science SA - AbbVie Inc. - AbGenomics International, Inc. - Actinium Pharmaceuticals, Inc. - Adamed Sp. z o.o. - Advaxis, Inc. - Advenchen Laboratories, LLC - Alchemia Limited - Allinky Biopharma - Amgen Inc. - Antibe Therapeutics, Inc. - Apexigen, Inc. - Aphios Corporation - Aposense Ltd. - Arisaph Pharmaceuticals, Inc. - ArQule, Inc. - Array BioPharma Inc. - Astellas Pharma Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca Plc - ATLAB Pharma SAS - AVEO Pharmaceuticals, Inc. - Basilea Pharmaceutica AG - Bavarian Nordic A/S - Baxalta Incorporated - Bayer AG - BeiGene(Beijing) Co.,Ltd - BioAtla, LLC - Biocon Limited - Bionomics Limited - Bionovis SA - Biotecnol, Inc. For more information visit http://www.researchandmarkets.com/research/44...tal_cancer About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
ADXS: 8.97 (-0.69), ARQL: 1.82 (-0.03), AMGN: 159.19 (-0.68), ATNM: 1.81 (-0.09), AZN: 29.73 (+0.06), AVEO: 1.04 (unch), ABBV: 65.00 (-0.09), BXLT: 46.02 (-0.18), ARRY: 3.79 (-0.06)
Parkinson's Disease Market - Pipeline Review, H2 2015 - 150+ Companies and Drug Profiles
M2 - Tue Feb 09, 6:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/6b8nmd/parkinsons) has announced the addition of the "Parkinson's Disease - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Parkinson's Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Parkinson's Disease and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Parkinson's Disease Overview - Therapeutics Development - Pipeline Products for Parkinson's Disease - Overview - Pipeline Products for Parkinson's Disease - Comparative Analysis - Parkinson's Disease - Therapeutics under Development by Companies - Parkinson's Disease - Therapeutics under Investigation by Universities/Institutes - Parkinson's Disease - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Parkinson's Disease - Products under Development by Companies - Parkinson's Disease - Products under Investigation by Universities/Institutes - Parkinson's Disease - Companies Involved in Therapeutics Development - Sample List of the 150 Companies Featured - AC Immune SA - Acelot, Inc. - Acorda Therapeutics, Inc. - Addex Therapeutics Ltd - Advinus Therapeutics Ltd. - Aeolus Pharmaceuticals, Inc. - AFFiRiS AG - Alexza Pharmaceuticals, Inc. - Allergan Plc - Amabiotics SAS - Amarantus Bioscience Holdings, Inc. - American Gene Technologies International Inc. - Amicus Therapeutics, Inc. - Anavex Life Sciences Corp. - Angita B.V. - Antoxis Limited - APeT Holding BV - Aposense Ltd. - Araclon Biotech, S.L. - ArmaGen,Inc. - Arrien Pharmaceuticals, LLC - Bial - Portela & Ca, S.A. - Bio-Modeling Systems SAS - BioArctic Neuroscience AB - Biogen, Inc. - Bionature E.A. Ltd. - Biopharm GmbH - Biotie Therapies Corp. - BrainStorm Cell Therapeutics Inc. - CalAsia Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/6b8nmd/parkinsons
AGN: 246.96 (-0.16), AVXL: 4.55 (-0.08), ACOR: 28.90 (-0.20), BCLI: 2.38 (-0.14), FOLD: 7.17 (-0.54), ALXA: 0.95 (unch)
Ovarian Cancer - Pipeline Review, H2 2015
M2 - Fri Feb 05, 9:33AM CST
Research and Markets (http://www.researchandmarkets.com/research/k64br7/ovarian_cancer) has announced the addition of the "Ovarian Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Ovarian Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ovarian Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Ovarian Cancer Overview - Therapeutics Development - Pipeline Products for Ovarian Cancer - Overview - Pipeline Products for Ovarian Cancer - Comparative Analysis - Ovarian Cancer - Therapeutics under Development by Companies - Ovarian Cancer - Therapeutics under Investigation by Universities/Institutes - Ovarian Cancer - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Ovarian Cancer - Products under Development by Companies - Ovarian Cancer - Products under Investigation by Universities/Institutes - Ovarian Cancer - Companies Involved in Therapeutics Development Companies Mentioned: - 3-V Biosciences, Inc. - 4SC AG - A. Menarini Industrie Farmaceutiche Riunite Srl - AB Science SA - AbbVie Inc. - Abeona Therapeutics, Inc. - AbGenomics International, Inc. - Acetylon Pharmaceuticals, Inc. - Adaptimmune Limited - Aduro BioTech, Inc. - Advanced Accelerator Applications SA - Advantagene, Inc. - Advaxis, Inc. - Advenchen Laboratories, LLC - Aeterna Zentaris Inc. - Agilvax, Inc. - Alchemia Limited - Alethia Biotherapeutics Inc. - Almac Discovery Limited - Ambrx, Inc. - Amgen Inc. - Anavex Life Sciences Corp. - ANP Technologies, Inc. - Antoxis Limited - Aphios Corporation - Aposense Ltd. - Aprea AB - arGEN-X BV - Armour Therapeutics Inc. - (200 Others) For more information visit http://www.researchandmarkets.com/research/k6...ian_cancer
ADXS: 8.97 (-0.69), ADRO: 11.73 (-0.54), AVXL: 4.55 (-0.08), AMBX: (), AMGN: 159.19 (-0.68), ABBV: 65.00 (-0.09), ABEO: 3.03 (-0.01), AAAP: 30.49 (+0.08)
Colon Cancer Pipeline Review, H2 2015
M2 - Wed Feb 03, 10:49AM CST
Research and Markets (http://www.researchandmarkets.com/research/pbmf4p/colon_cancer) has announced the addition of the "Colon Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Colon Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Colon Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Colon Cancer Overview - Therapeutics Development - Pipeline Products for Colon Cancer - Overview - Pipeline Products for Colon Cancer - Comparative Analysis - Colon Cancer - Therapeutics under Development by Companies - Colon Cancer - Therapeutics under Investigation by Universities/Institutes - Colon Cancer - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Colon Cancer - Products under Development by Companies - Colon Cancer - Products under Investigation by Universities/Institutes - Colon Cancer - Companies Involved in Therapeutics Development Companies Mentioned - Partial List - ACF Pharmaceuticals, LLC - Aduro BioTech, Inc. - Advanced Proteome Therapeutics Corporation - Advenchen Laboratories, LLC - Agenus, Inc. - AGV Discovery, SAS - AIMM Therapeutics B.V. - Alethia Biotherapeutics Inc. - Ambrx, Inc. - Anavex Life Sciences Corp. - AndroScience Corporation - ANP Technologies, Inc. - Aphios Corporation - Aposense Ltd. - Aptose Biosciences Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca Plc - Aurigene Discovery Technologies Limited - Bio-Path Holdings, Inc. - Biogazelle - Bioncotech Therapeutics S.L. - Caladrius Biosciences, Inc. - Can-Fite BioPharma Ltd. - Carna Biosciences, Inc. - Celyad SA - Critical Outcome Technologies Inc. - CureFAKtor Pharmaceuticals, LLC For more information visit http://www.researchandmarkets.com/research/pb...lon_cancer
ADRO: 11.73 (-0.54), AMBX: (), CLBS: 0.54 (+0.01), CANF: 3.07 (+0.17), APTO: 2.70 (+0.04), AVXL: 4.55 (-0.08), BPTH: 2.50 (unch), AZN: 29.73 (+0.06), CYAD: 58.66 (+0.36)
World Small-Cell Lung Cancer Therapeutic Development Pipeline Review, H2 2015
M2 - Fri Jan 29, 5:03AM CST
Research and Markets (http://www.researchandmarkets.com/research/3zbk4w/smallcell_lung) has announced the addition of the "Small-Cell Lung Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Small-Cell Lung Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Small-Cell Lung Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Small-Cell Lung Cancer Overview - Therapeutics Development - Pipeline Products for Small-Cell Lung Cancer - Overview - Pipeline Products for Small-Cell Lung Cancer - Comparative Analysis - Small-Cell Lung Cancer - Therapeutics under Development by Companies - Small-Cell Lung Cancer - Therapeutics under Investigation by Universities/Institutes - Small-Cell Lung Cancer - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Small-Cell Lung Cancer - Products under Development by Companies - Small-Cell Lung Cancer - Products under Investigation by Universities/Institutes - Small-Cell Lung Cancer - Companies Involved in Therapeutics Development - 3B Pharmaceuticals GmbH - 4SC AG - A. Menarini Industrie Farmaceutiche Riunite Srl - AbbVie Inc. - Alchemia Limited - Amgen Inc. - Andarix Pharmaceuticals, Inc. - Aposense Ltd. - Array BioPharma Inc. - Astellas Pharma Inc. - BIND Therapeutics, Inc. - Blend Therapeutics, Inc. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Eli Lilly and Company - Exelixis, Inc. - F. Hoffmann-La Roche Ltd. - G1 Therapeutics, Inc. - Genzyme Corporation - GlaxoSmithKline Plc - Karyopharm Therapeutics, Inc. - Kolltan Pharmaceuticals, Inc. - Kyowa Hakko Kirin Co., Ltd. - Lindis Biotech GmbH - MabVax Therapeutics Holdings, Inc. - MedImmune, LLC - MEI Pharma, Inc. - Merck & Co., Inc. - NanoSmart Pharmaceuticals, Inc. - Nippon Kayaku Co., Ltd. - Novartis AG - Pfizer Inc. - Polaris Pharmaceuticals, Inc. - Rexahn Pharmaceuticals, Inc. - Spectrum Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/3z...lcell_lung
RNN: 0.31 (-0.01), PFE: 34.69 (-0.18), AMGN: 159.19 (-0.68), SPPI: 7.34 (-0.18), BIND: 0.44 (unch), LLY: 75.12 (-0.34), BMY: 72.89 (-0.11), GSK: 42.89 (+0.48), MEIP: 1.45 (+0.03), MRK: 56.64 (-0.18), ABBV: 65.00 (-0.09), NVS: 80.95 (+0.24), KPTI: 9.25 (-0.45), ARRY: 3.79 (-0.06), EXEL: 6.59 (-0.17)
Ovarian Cancer Pipeline Review, H1 2015 - Reviews Key Players Involved in the Therapeutics Development for Ovarian Cancer
M2 - Mon Aug 17, 5:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/752ksw/ovarian_cancer) has announced the addition of the "Ovarian Cancer - Pipeline Review, H1 2015" report to their offering. Summary This, Ovarian Cancer - Pipeline Review, H1 2015', provides an overview of the Ovarian Cancer's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Ovarian Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ovarian Cancer and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Scope - The report provides a snapshot of the global therapeutic landscape of Ovarian Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report summarizes all the dormant and discontinued pipeline projects Key Topics Covered: Overview Therapeutics Development Therapeutics under Development by Companies Therapeutics under Investigation by Universities/Institutes Pipeline Products Glance Products under Development by Companies Products under Investigation by Universities/Institutes Companies Involved in Therapeutics Development Therapeutics Assessment Drug Profiles Recent Pipeline Updates Dormant Projects Discontinued Products Product Development Milestones Companies Mentioned - 3-V Biosciences, Inc. - A. Menarini Industrie Farmaceutiche Riunite Srl - AbbVie Inc. - Abeona Therapeutics, Inc. - AbGenomics International, Inc. - Acceleron Pharma, Inc. - Adaptimmune Limited - Aduro BioTech, Inc. - Advanced Accelerator Applications SA - Advantagene, Inc. - Advaxis, Inc. - Advenchen Laboratories, LLC - Aeterna Zentaris Inc. - Agilvax, Inc. - Alchemia Limited - Alethia Biotherapeutics Inc. - Almac Discovery Limited - Ambrx, Inc. - Amgen Inc. - Amorfix Life Sciences Ltd. - Anavex Life Sciences Corp. - Angstrom Pharmaceuticals, Inc. - ANP Technologies, Inc. - Aphios Corporation - Aposense Ltd. - Aprea AB - arGEN-X BV - Armour Therapeutics Inc. - Arog Pharmaceuticals, Inc. - Array BioPharma Inc. - Arrien Pharmaceuticals, LLC - Ascenta Therapeutics, Inc. - Astellas Pharma Inc. For more information visit http://www.researchandmarkets.com/research/75...ian_cancer
ADXS: 8.97 (-0.69), ADRO: 11.73 (-0.54), AMBX: (), AMGN: 159.19 (-0.68), ABEO: 3.03 (-0.01), AAAP: 30.49 (+0.08), AVXL: 4.55 (-0.08), ABBV: 65.00 (-0.09), PMN.TO: 0.10 (+0.01), ARRY: 3.79 (-0.06), XLRN: 36.19 (-1.04)
Colon Cancer Pipeline Review, H1 2015 - Reviews Key Players Involved in the Therapeutics Development for Colon Cancer and Enlists all Their Major and Minor Projects
M2 - Fri Aug 14, 8:52AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6lqjnr/colon_cancer) has announced the addition of the "Colon Cancer - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Colon Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Colon Cancer and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Scope - The report provides a snapshot of the global therapeutic landscape of Colon Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities Key Topics Covered: - Introduction - Colon Cancer Overview - Therapeutics Development - Therapeutics under Development by Companies - Therapeutics under Investigation by Universities/Institutes - Pipeline Products Glance - Products under Development by Companies - Products under Investigation by Universities/Institutes - Companies Involved in Therapeutics Development - Therapeutics Assessment - Drug Profiles - Recent Pipeline Updates - Dormant Projects - Discontinued Products - Product Development Milestones Companies Mentioned - Aduro BioTech, Inc. - Advanced Proteome Therapeutics Corporation - Advenchen Laboratories, LLC - AGV Discovery, SAS - AIMM Therapeutics B.V. - Alethia Biotherapeutics Inc. - AlphaVax, Inc. - Ambrx, Inc. - Anavex Life Sciences Corp. - AndroScience Corporation - ANP Technologies, Inc. - Aphios Corporation - Apogenix GmbH - Aposense Ltd. - AstraZeneca Plc - Aurigene Discovery Technologies Limited - Bavarian Nordic A/S - Bio-Path Holdings, Inc. - Bioncotech Therapeutics S.L. - Bionomics Limited - Carna Biosciences, Inc. - Celyad - Cold Genesys, Inc. For more information visit http://www.researchandmarkets.com/research/6l...lon_cancer
ADRO: 11.73 (-0.54), AVXL: 4.55 (-0.08), BPTH: 2.50 (unch), AMBX: (), AZN: 29.73 (+0.06), CYAD: 58.66 (+0.36)
Small-Cell Lung Cancer - Pipeline Review, H1 2015
M2 - Fri Jul 31, 9:38AM CDT
Research and Markets (http://www.researchandmarkets.com/research/szb6j5/smallcell_lung) has announced the addition of the "Small-Cell Lung Cancer - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Small-Cell Lung Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Small-Cell Lung Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Partial List - A. Menarini Industrie Farmaceutiche Riunite Srl - AbbVie Inc. - Alchemia Limited - Amgen Inc. - Aposense Ltd. - Array BioPharma Inc. - Astellas Pharma Inc. - AstraZeneca Plc - AVEO Pharmaceuticals, Inc. - Bayer AG - BIND Therapeutics, Inc. - Blend Therapeutics, Inc. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Cantex Pharmaceuticals, Inc. - Celator Pharmaceuticals, Inc. - CellAct Pharma GmbH - Cerulean Pharma, Inc. - Cornerstone Pharmaceuticals, Inc. - Critical Outcome Technologies Inc. - CytRx Corporation - Eisai Co., Ltd. - Eli Lilly and Company - Exelixis, Inc. - F. Hoffmann-La Roche Ltd. - GlaxoSmithKline Plc - Hutchison MediPharma Limited - ImmunoCellular Therapeutics, Ltd. - Immunomedics, Inc. - Inbiopro Solutions Pvt. Ltd For more information visit http://www.researchandmarkets.com/research/sz...lcell_lung
IMMU: 4.52 (-0.78), CERU: 2.43 (-0.08), AMGN: 159.19 (-0.68), LLY: 75.12 (-0.34), BIND: 0.44 (unch), GSK: 42.89 (+0.48), BMY: 72.89 (-0.11), IMUC: 0.25 (+0.01), AZN: 29.73 (+0.06), CYTR: 2.77 (-0.20), AVEO: 1.04 (unch), ABBV: 65.00 (-0.09), EXEL: 6.59 (-0.17), ARRY: 3.79 (-0.06)
Aposense Ltd. - Product Pipeline Review - 2014
PR Newswire - Thu Nov 20, 6:47AM CST
Summary
Pancreatic Cancer Pipeline Review, H2 2015
M2 - Tue Feb 09, 10:18AM CST
Research and Markets (http://www.researchandmarkets.com/research/r58xq3/pancreatic_cancer) has announced the addition of the "Pancreatic Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pancreatic Cancerand special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Pancreatic CancerOverview - Therapeutics Development - Pipeline Products for Pancreatic Cancer - Overview - Pipeline Products for Pancreatic Cancer - Comparative Analysis - Pancreatic Cancer - Therapeutics under Development by Companies - Pancreatic Cancer - Therapeutics under Investigation by Universities/Institutes - Pancreatic Cancer - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Pancreatic Cancer - Products under Development by Companies - Pancreatic Cancer - Products under Investigation by Universities/Institutes - Pancreatic Cancer - Companies Involved in Therapeutics Development Companies Mentioned - Partial List - 3-V Biosciences, Inc. - 3B Pharmaceuticals GmbH - 4SC AG - AB Science SA - AbbVie Inc. - AbGenomics International, Inc. - Ability Pharma, SL - Acetylon Pharmaceuticals, Inc. - ACF Pharmaceuticals, LLC - Adamed Sp. z o.o. - Adamis Pharmaceuticals Corporation - Aduro BioTech, Inc. - Advantagene, Inc. - Advaxis, Inc. - Agenus, Inc. - AGV Discovery, SAS - AIMM Therapeutics B.V. - Alchemia Limited - Alethia Biotherapeutics Inc. - Allinky Biopharma - Almac Discovery Limited - Altor BioScience Corporation - Ambrx, Inc. - Amgen Inc. - Anavex Life Sciences Corp. - Andarix Pharmaceuticals, Inc. - ANP Technologies, Inc. - APEIRON Biologics AG - Apexigen, Inc. - Aphios Corporation - APIM Therapeutics AS - Apogenix GmbH - Aposense Ltd. - Arch Biopartners, Inc. - Argon Pharma S.L. For more information visit http://www.researchandmarkets.com/research/r5...tic_cancer
ADXS: 8.97 (-0.69), ADRO: 11.73 (-0.54), AVXL: 4.55 (-0.08), AMBX: (), ACH: 7.64 (-0.02), AMGN: 159.19 (-0.68), ADMP: 8.86 (unch), ABBV: 65.00 (-0.09)
Global Melanoma Pipeline Review 2015
M2 - Tue Feb 09, 10:12AM CST
Research and Markets (http://www.researchandmarkets.com/research/xdhrqg/melanoma) has announced the addition of the "Melanoma - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Melanomaand special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - MelanomaOverview - Therapeutics Development - Pipeline Products for Melanoma - Overview - Pipeline Products for Melanoma - Comparative Analysis - Melanoma - Therapeutics under Development by Companies - Melanoma - Therapeutics under Investigation by Universities/Institutes - Melanoma - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Melanoma - Products under Development by Companies - Melanoma - Products under Investigation by Universities/Institutes - Melanoma - Companies Involved in Therapeutics Development Companies Mentioned - Sample List - AB Science SA - AbbVie Inc. - ACF Pharmaceuticals, LLC - Adamis Pharmaceuticals Corporation - Adaptimmune Limited - Aduro BioTech, Inc. - Advaxis, Inc. - Aeterna Zentaris Inc. - Affichem SA - Agalimmune Ltd - Agenus, Inc. - Agilvax, Inc. - AGV Discovery, SAS - AIMM Therapeutics B.V. - Alethia Biotherapeutics Inc. - Altor BioScience Corporation - Amgen Inc. - Anavex Life Sciences Corp. - Antigen Express, Inc. - APEIRON Biologics AG - Aphios Corporation - APO-T B.V. - Aposense Ltd. - Applied Immune Technologies Ltd - Aptose Biosciences Inc. - Arisaph Pharmaceuticals, Inc. - Array BioPharma Inc. - Arrowhead Research Corporation - Astex Pharmaceuticals, Inc. - AstraZeneca Plc - Aurigene Discovery Technologies Limited - Axelar AB - Azaya Therapeutics, Inc. - Basilea Pharmaceutica AG For more information visit http://www.researchandmarkets.com/research/xdhrqg/melanoma
ADXS: 8.97 (-0.69), ADRO: 11.73 (-0.54), ARWR: 6.12 (-0.06), ADMP: 8.86 (unch), AMGN: 159.19 (-0.68), APTO: 2.70 (+0.04), AVXL: 4.55 (-0.08), AZN: 29.73 (+0.06), ABBV: 65.00 (-0.09), ARRY: 3.79 (-0.06)
Colorectal Cancer Therapeutics Development Pipeline Review, H2 2015
M2 - Tue Feb 09, 6:40AM CST
Research and Markets (http://www.researchandmarkets.com/research/44bmjz/colorectal_cancer) has announced the addition of the "Colorectal Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Colorectal Cancerand special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Colorectal CancerOverview - Therapeutics Development - Pipeline Products for Colorectal Cancer- Overview - Pipeline Products for Colorectal Cancer- Comparative Analysis - Colorectal Cancer- Therapeutics under Development by Companies - Colorectal Cancer- Therapeutics under Investigation by Universities/Institutes - Colorectal Cancer- Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Colorectal Cancer- Products under Development by Companies - Colorectal Cancer- Products under Investigation by Universities/Institutes - Colorectal Cancer- Companies Involved in Therapeutics Development Companies Mentioned - Sample List of the 200 Companies Featured - 2cureX ApS - 3-V Biosciences, Inc. - 4SC AG - AB Science SA - AbbVie Inc. - AbGenomics International, Inc. - Actinium Pharmaceuticals, Inc. - Adamed Sp. z o.o. - Advaxis, Inc. - Advenchen Laboratories, LLC - Alchemia Limited - Allinky Biopharma - Amgen Inc. - Antibe Therapeutics, Inc. - Apexigen, Inc. - Aphios Corporation - Aposense Ltd. - Arisaph Pharmaceuticals, Inc. - ArQule, Inc. - Array BioPharma Inc. - Astellas Pharma Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca Plc - ATLAB Pharma SAS - AVEO Pharmaceuticals, Inc. - Basilea Pharmaceutica AG - Bavarian Nordic A/S - Baxalta Incorporated - Bayer AG - BeiGene(Beijing) Co.,Ltd - BioAtla, LLC - Biocon Limited - Bionomics Limited - Bionovis SA - Biotecnol, Inc. For more information visit http://www.researchandmarkets.com/research/44...tal_cancer About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
ADXS: 8.97 (-0.69), ARQL: 1.82 (-0.03), AMGN: 159.19 (-0.68), ATNM: 1.81 (-0.09), AZN: 29.73 (+0.06), AVEO: 1.04 (unch), ABBV: 65.00 (-0.09), BXLT: 46.02 (-0.18), ARRY: 3.79 (-0.06)
Parkinson's Disease Market - Pipeline Review, H2 2015 - 150+ Companies and Drug Profiles
M2 - Tue Feb 09, 6:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/6b8nmd/parkinsons) has announced the addition of the "Parkinson's Disease - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Parkinson's Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Parkinson's Disease and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Parkinson's Disease Overview - Therapeutics Development - Pipeline Products for Parkinson's Disease - Overview - Pipeline Products for Parkinson's Disease - Comparative Analysis - Parkinson's Disease - Therapeutics under Development by Companies - Parkinson's Disease - Therapeutics under Investigation by Universities/Institutes - Parkinson's Disease - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Parkinson's Disease - Products under Development by Companies - Parkinson's Disease - Products under Investigation by Universities/Institutes - Parkinson's Disease - Companies Involved in Therapeutics Development - Sample List of the 150 Companies Featured - AC Immune SA - Acelot, Inc. - Acorda Therapeutics, Inc. - Addex Therapeutics Ltd - Advinus Therapeutics Ltd. - Aeolus Pharmaceuticals, Inc. - AFFiRiS AG - Alexza Pharmaceuticals, Inc. - Allergan Plc - Amabiotics SAS - Amarantus Bioscience Holdings, Inc. - American Gene Technologies International Inc. - Amicus Therapeutics, Inc. - Anavex Life Sciences Corp. - Angita B.V. - Antoxis Limited - APeT Holding BV - Aposense Ltd. - Araclon Biotech, S.L. - ArmaGen,Inc. - Arrien Pharmaceuticals, LLC - Bial - Portela & Ca, S.A. - Bio-Modeling Systems SAS - BioArctic Neuroscience AB - Biogen, Inc. - Bionature E.A. Ltd. - Biopharm GmbH - Biotie Therapies Corp. - BrainStorm Cell Therapeutics Inc. - CalAsia Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/6b8nmd/parkinsons
AGN: 246.96 (-0.16), AVXL: 4.55 (-0.08), ACOR: 28.90 (-0.20), BCLI: 2.38 (-0.14), FOLD: 7.17 (-0.54), ALXA: 0.95 (unch)
Ovarian Cancer - Pipeline Review, H2 2015
M2 - Fri Feb 05, 9:33AM CST
Research and Markets (http://www.researchandmarkets.com/research/k64br7/ovarian_cancer) has announced the addition of the "Ovarian Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Ovarian Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ovarian Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Ovarian Cancer Overview - Therapeutics Development - Pipeline Products for Ovarian Cancer - Overview - Pipeline Products for Ovarian Cancer - Comparative Analysis - Ovarian Cancer - Therapeutics under Development by Companies - Ovarian Cancer - Therapeutics under Investigation by Universities/Institutes - Ovarian Cancer - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Ovarian Cancer - Products under Development by Companies - Ovarian Cancer - Products under Investigation by Universities/Institutes - Ovarian Cancer - Companies Involved in Therapeutics Development Companies Mentioned: - 3-V Biosciences, Inc. - 4SC AG - A. Menarini Industrie Farmaceutiche Riunite Srl - AB Science SA - AbbVie Inc. - Abeona Therapeutics, Inc. - AbGenomics International, Inc. - Acetylon Pharmaceuticals, Inc. - Adaptimmune Limited - Aduro BioTech, Inc. - Advanced Accelerator Applications SA - Advantagene, Inc. - Advaxis, Inc. - Advenchen Laboratories, LLC - Aeterna Zentaris Inc. - Agilvax, Inc. - Alchemia Limited - Alethia Biotherapeutics Inc. - Almac Discovery Limited - Ambrx, Inc. - Amgen Inc. - Anavex Life Sciences Corp. - ANP Technologies, Inc. - Antoxis Limited - Aphios Corporation - Aposense Ltd. - Aprea AB - arGEN-X BV - Armour Therapeutics Inc. - (200 Others) For more information visit http://www.researchandmarkets.com/research/k6...ian_cancer
ADXS: 8.97 (-0.69), ADRO: 11.73 (-0.54), AVXL: 4.55 (-0.08), AMBX: (), AMGN: 159.19 (-0.68), ABBV: 65.00 (-0.09), ABEO: 3.03 (-0.01), AAAP: 30.49 (+0.08)
Colon Cancer Pipeline Review, H2 2015
M2 - Wed Feb 03, 10:49AM CST
Research and Markets (http://www.researchandmarkets.com/research/pbmf4p/colon_cancer) has announced the addition of the "Colon Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Colon Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Colon Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Colon Cancer Overview - Therapeutics Development - Pipeline Products for Colon Cancer - Overview - Pipeline Products for Colon Cancer - Comparative Analysis - Colon Cancer - Therapeutics under Development by Companies - Colon Cancer - Therapeutics under Investigation by Universities/Institutes - Colon Cancer - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Colon Cancer - Products under Development by Companies - Colon Cancer - Products under Investigation by Universities/Institutes - Colon Cancer - Companies Involved in Therapeutics Development Companies Mentioned - Partial List - ACF Pharmaceuticals, LLC - Aduro BioTech, Inc. - Advanced Proteome Therapeutics Corporation - Advenchen Laboratories, LLC - Agenus, Inc. - AGV Discovery, SAS - AIMM Therapeutics B.V. - Alethia Biotherapeutics Inc. - Ambrx, Inc. - Anavex Life Sciences Corp. - AndroScience Corporation - ANP Technologies, Inc. - Aphios Corporation - Aposense Ltd. - Aptose Biosciences Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca Plc - Aurigene Discovery Technologies Limited - Bio-Path Holdings, Inc. - Biogazelle - Bioncotech Therapeutics S.L. - Caladrius Biosciences, Inc. - Can-Fite BioPharma Ltd. - Carna Biosciences, Inc. - Celyad SA - Critical Outcome Technologies Inc. - CureFAKtor Pharmaceuticals, LLC For more information visit http://www.researchandmarkets.com/research/pb...lon_cancer
ADRO: 11.73 (-0.54), AMBX: (), CLBS: 0.54 (+0.01), CANF: 3.07 (+0.17), APTO: 2.70 (+0.04), AVXL: 4.55 (-0.08), BPTH: 2.50 (unch), AZN: 29.73 (+0.06), CYAD: 58.66 (+0.36)
World Small-Cell Lung Cancer Therapeutic Development Pipeline Review, H2 2015
M2 - Fri Jan 29, 5:03AM CST
Research and Markets (http://www.researchandmarkets.com/research/3zbk4w/smallcell_lung) has announced the addition of the "Small-Cell Lung Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Small-Cell Lung Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Small-Cell Lung Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Small-Cell Lung Cancer Overview - Therapeutics Development - Pipeline Products for Small-Cell Lung Cancer - Overview - Pipeline Products for Small-Cell Lung Cancer - Comparative Analysis - Small-Cell Lung Cancer - Therapeutics under Development by Companies - Small-Cell Lung Cancer - Therapeutics under Investigation by Universities/Institutes - Small-Cell Lung Cancer - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Small-Cell Lung Cancer - Products under Development by Companies - Small-Cell Lung Cancer - Products under Investigation by Universities/Institutes - Small-Cell Lung Cancer - Companies Involved in Therapeutics Development - 3B Pharmaceuticals GmbH - 4SC AG - A. Menarini Industrie Farmaceutiche Riunite Srl - AbbVie Inc. - Alchemia Limited - Amgen Inc. - Andarix Pharmaceuticals, Inc. - Aposense Ltd. - Array BioPharma Inc. - Astellas Pharma Inc. - BIND Therapeutics, Inc. - Blend Therapeutics, Inc. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Eli Lilly and Company - Exelixis, Inc. - F. Hoffmann-La Roche Ltd. - G1 Therapeutics, Inc. - Genzyme Corporation - GlaxoSmithKline Plc - Karyopharm Therapeutics, Inc. - Kolltan Pharmaceuticals, Inc. - Kyowa Hakko Kirin Co., Ltd. - Lindis Biotech GmbH - MabVax Therapeutics Holdings, Inc. - MedImmune, LLC - MEI Pharma, Inc. - Merck & Co., Inc. - NanoSmart Pharmaceuticals, Inc. - Nippon Kayaku Co., Ltd. - Novartis AG - Pfizer Inc. - Polaris Pharmaceuticals, Inc. - Rexahn Pharmaceuticals, Inc. - Spectrum Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/3z...lcell_lung
RNN: 0.31 (-0.01), PFE: 34.69 (-0.18), AMGN: 159.19 (-0.68), SPPI: 7.34 (-0.18), BIND: 0.44 (unch), LLY: 75.12 (-0.34), BMY: 72.89 (-0.11), GSK: 42.89 (+0.48), MEIP: 1.45 (+0.03), MRK: 56.64 (-0.18), ABBV: 65.00 (-0.09), NVS: 80.95 (+0.24), KPTI: 9.25 (-0.45), ARRY: 3.79 (-0.06), EXEL: 6.59 (-0.17)
Ovarian Cancer Pipeline Review, H1 2015 - Reviews Key Players Involved in the Therapeutics Development for Ovarian Cancer
M2 - Mon Aug 17, 5:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/752ksw/ovarian_cancer) has announced the addition of the "Ovarian Cancer - Pipeline Review, H1 2015" report to their offering. Summary This, Ovarian Cancer - Pipeline Review, H1 2015', provides an overview of the Ovarian Cancer's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Ovarian Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ovarian Cancer and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Scope - The report provides a snapshot of the global therapeutic landscape of Ovarian Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report summarizes all the dormant and discontinued pipeline projects Key Topics Covered: Overview Therapeutics Development Therapeutics under Development by Companies Therapeutics under Investigation by Universities/Institutes Pipeline Products Glance Products under Development by Companies Products under Investigation by Universities/Institutes Companies Involved in Therapeutics Development Therapeutics Assessment Drug Profiles Recent Pipeline Updates Dormant Projects Discontinued Products Product Development Milestones Companies Mentioned - 3-V Biosciences, Inc. - A. Menarini Industrie Farmaceutiche Riunite Srl - AbbVie Inc. - Abeona Therapeutics, Inc. - AbGenomics International, Inc. - Acceleron Pharma, Inc. - Adaptimmune Limited - Aduro BioTech, Inc. - Advanced Accelerator Applications SA - Advantagene, Inc. - Advaxis, Inc. - Advenchen Laboratories, LLC - Aeterna Zentaris Inc. - Agilvax, Inc. - Alchemia Limited - Alethia Biotherapeutics Inc. - Almac Discovery Limited - Ambrx, Inc. - Amgen Inc. - Amorfix Life Sciences Ltd. - Anavex Life Sciences Corp. - Angstrom Pharmaceuticals, Inc. - ANP Technologies, Inc. - Aphios Corporation - Aposense Ltd. - Aprea AB - arGEN-X BV - Armour Therapeutics Inc. - Arog Pharmaceuticals, Inc. - Array BioPharma Inc. - Arrien Pharmaceuticals, LLC - Ascenta Therapeutics, Inc. - Astellas Pharma Inc. For more information visit http://www.researchandmarkets.com/research/75...ian_cancer
ADXS: 8.97 (-0.69), ADRO: 11.73 (-0.54), AMBX: (), AMGN: 159.19 (-0.68), ABEO: 3.03 (-0.01), AAAP: 30.49 (+0.08), AVXL: 4.55 (-0.08), ABBV: 65.00 (-0.09), PMN.TO: 0.10 (+0.01), ARRY: 3.79 (-0.06), XLRN: 36.19 (-1.04)
Colon Cancer Pipeline Review, H1 2015 - Reviews Key Players Involved in the Therapeutics Development for Colon Cancer and Enlists all Their Major and Minor Projects
M2 - Fri Aug 14, 8:52AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6lqjnr/colon_cancer) has announced the addition of the "Colon Cancer - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Colon Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Colon Cancer and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Scope - The report provides a snapshot of the global therapeutic landscape of Colon Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities Key Topics Covered: - Introduction - Colon Cancer Overview - Therapeutics Development - Therapeutics under Development by Companies - Therapeutics under Investigation by Universities/Institutes - Pipeline Products Glance - Products under Development by Companies - Products under Investigation by Universities/Institutes - Companies Involved in Therapeutics Development - Therapeutics Assessment - Drug Profiles - Recent Pipeline Updates - Dormant Projects - Discontinued Products - Product Development Milestones Companies Mentioned - Aduro BioTech, Inc. - Advanced Proteome Therapeutics Corporation - Advenchen Laboratories, LLC - AGV Discovery, SAS - AIMM Therapeutics B.V. - Alethia Biotherapeutics Inc. - AlphaVax, Inc. - Ambrx, Inc. - Anavex Life Sciences Corp. - AndroScience Corporation - ANP Technologies, Inc. - Aphios Corporation - Apogenix GmbH - Aposense Ltd. - AstraZeneca Plc - Aurigene Discovery Technologies Limited - Bavarian Nordic A/S - Bio-Path Holdings, Inc. - Bioncotech Therapeutics S.L. - Bionomics Limited - Carna Biosciences, Inc. - Celyad - Cold Genesys, Inc. For more information visit http://www.researchandmarkets.com/research/6l...lon_cancer
ADRO: 11.73 (-0.54), AVXL: 4.55 (-0.08), BPTH: 2.50 (unch), AMBX: (), AZN: 29.73 (+0.06), CYAD: 58.66 (+0.36)
Small-Cell Lung Cancer - Pipeline Review, H1 2015
M2 - Fri Jul 31, 9:38AM CDT
Research and Markets (http://www.researchandmarkets.com/research/szb6j5/smallcell_lung) has announced the addition of the "Small-Cell Lung Cancer - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Small-Cell Lung Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Small-Cell Lung Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Partial List - A. Menarini Industrie Farmaceutiche Riunite Srl - AbbVie Inc. - Alchemia Limited - Amgen Inc. - Aposense Ltd. - Array BioPharma Inc. - Astellas Pharma Inc. - AstraZeneca Plc - AVEO Pharmaceuticals, Inc. - Bayer AG - BIND Therapeutics, Inc. - Blend Therapeutics, Inc. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Cantex Pharmaceuticals, Inc. - Celator Pharmaceuticals, Inc. - CellAct Pharma GmbH - Cerulean Pharma, Inc. - Cornerstone Pharmaceuticals, Inc. - Critical Outcome Technologies Inc. - CytRx Corporation - Eisai Co., Ltd. - Eli Lilly and Company - Exelixis, Inc. - F. Hoffmann-La Roche Ltd. - GlaxoSmithKline Plc - Hutchison MediPharma Limited - ImmunoCellular Therapeutics, Ltd. - Immunomedics, Inc. - Inbiopro Solutions Pvt. Ltd For more information visit http://www.researchandmarkets.com/research/sz...lcell_lung
IMMU: 4.52 (-0.78), CERU: 2.43 (-0.08), AMGN: 159.19 (-0.68), LLY: 75.12 (-0.34), BIND: 0.44 (unch), GSK: 42.89 (+0.48), BMY: 72.89 (-0.11), IMUC: 0.25 (+0.01), AZN: 29.73 (+0.06), CYTR: 2.77 (-0.20), AVEO: 1.04 (unch), ABBV: 65.00 (-0.09), EXEL: 6.59 (-0.17), ARRY: 3.79 (-0.06)
Aposense Ltd. - Product Pipeline Review - 2014
PR Newswire - Thu Nov 20, 6:47AM CST
Summary
